EVE.SW EvoNext S.A. (SIX) pre-market +9.56% to CHF 0.85 Feb 2026: earnings in focus

The EVE.SW stock is a pre-market top gainer on 10 Feb 2026, rising +9.56% to CHF 0.85 after early trades showed buying interest ahead of a scheduled earnings release. EvoNext Holdings S.A. (EVE.SW) trades on the SIX in Switzerland and closed the prior session at CHF 0.77. Volume is thin at 278 shares versus an average of 6,163, so moves can be amplified. Investors are watching the company’s upcoming earnings date on 20 Feb 2026 for guidance and potential catalysts in the biotechnology healthcare sector.

Pre-market movers: EVE.SW stock price action and drivers

EVE.SW stock opened pre-market at CHF 0.77 and is trading at CHF 0.85, a +9.56% intraday change from the previous close of CHF 0.77. Day range so far is CHF 0.77 to CHF 0.85, with a market capitalisation of CHF 6,115,396.00 and 7,211,552.00 shares outstanding. The jump reflects low liquidity—today’s volume of 278.00 is well under the 6,163.00 average volume—and positioning ahead of the 20 Feb 2026 earnings announcement.

Fundamentals and valuation: EVE.SW stock metrics

EvoNext is in Healthcare, Biotechnology, and EVE.SW stock shows conservative balance-sheet metrics with cash per share CHF 0.87 and book value per share CHF 0.86. Trailing EPS is -0.12, producing a negative PE of -7.07, while the price-to-book ratio is 0.98. The company reports a strong current ratio of 8.34, low leverage (debt to equity 0.00), and enterprise value listed as CHF -197,604.00. These figures suggest capital preservation but continued operating losses.

Technicals and trading: EVE.SW stock trends

Technically, EVE.SW stock shows a neutral momentum setup: RSI 52.91, ADX 29.43 indicating a strong trend environment, and CCI 221.05 signalling short-term overbought conditions. Bollinger Bands sit at Upper 0.85, Middle 0.80, Lower 0.75, and the 50-day average price is CHF 0.80 versus the 200-day CHF 0.98. The low relative volume (relVolume 0.04) warns that moves are fragile and can reverse on light trade.

Meyka AI rates EVE.SW stock and forecast

Meyka AI rates EVE.SW with a score out of 100: 68.10 | Grade B | HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamental trends. Meyka AI’s forecast model projects a yearly price of CHF 2.33, compared with the current price CHF 0.848, implying an upside of +174.66%. Forecasts are model-based projections and not guarantees. Note: these grades are not guaranteed and we are not financial advisors.

Catalysts and risks for EVE.SW stock

Near-term catalysts include the 20 Feb 2026 earnings report and any product or regulatory updates in EvoNext’s nutritional and wellness pipeline. Sector strength in Healthcare (sector YTD +4.47%) could support gains. Key risks are low liquidity, continued operating losses, and historical share dilution—EPS remains negative and revenue per share shows CHF 0.00 on TTM basis. Investors should weigh catalyst-driven swings against thin trading and biotech volatility.

Price targets and scenario analysis for EVE.SW stock

For planning, we present two scenarios: a conservative 12-month price target at CHF 1.20 (implied upside +41.51%) if the earnings beat and liquidity improves; and a model-driven target of CHF 2.33 over 12 months from Meyka AI (implied upside +174.66% vs CHF 0.848). Use stop levels given short-term overbought signals; consider position sizing due to low average volume of 6,163.00 shares.

Final Thoughts

EVE.SW stock is a pre-market top gainer on 10 Feb 2026, up +9.56% to CHF 0.85 on light volume and ahead of an earnings report on 20 Feb 2026. Fundamentals show a strong cash position (cash per share CHF 0.87) and low leverage, but persistent negative EPS (-0.12) and thin liquidity make volatility likely. Meyka AI’s forecast model projects CHF 2.33 yearly versus the current price CHF 0.848, an implied upside of +174.66%, while a more conservative 12-month target is CHF 1.20 (+41.51%). These figures frame a high-risk, catalyst-driven trade: potential for large gains if earnings or pipeline news beat expectations, but material downside if liquidity dries up or results disappoint. For readers tracking EVE.SW stock, prioritize small position sizes, clear stop-loss rules, and monitor sector momentum and volume into the earnings release. For company details visit EvoNext website and the company LinkedIn profile. See the Meyka stock page for live updates: EVE.SW on Meyka. Meyka AI provides this AI-powered market analysis as information, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.